01Market Overview
Most U.S. benchmarks traded under pressure as risk sentiment continued to sour for AI-linked exposure. More selling in the beleaguered Chinese stock market spilled over into markets abroad, while government bond yields retreated for a second week and earnings reports were strong.
02U.S. Markets
The IPOX® 100 U.S. (IPXO), the U.S. IPO benchmark, declined 0.48% to +3.38% YTD last week, with the portfolio remaining under pressure after a failed attempt toward midweek to retake the key 200-trading-day average.
In what continues to be a mirror image of much of last year, equally weighted returns diverged sharply from the index, with 58% of holdings recording a positive week and an average (median) return of +1.11% (+1.00%).
We note big declines in heavyweights GE Vernova (GEV US: −11.53%), an electrification leader, and storage device maker Sandisk (SNDK US: −4.72%) drove much of the weakness, while stellar earnings failed to sustain the strength in industrial SpaceX (SPCX US: +1.00%).
In focus / Health care
VeraDermics in the spotlight
VeraDermics (MANE) vs. serial IPO acquirer Eli Lilly (LLY).
We note another big week for VeraDermics (MANE US: +27.53%), a New Haven, CT-based clinical-stage biopharma working on the next frontier in health care: treating hair loss. The stock has now gained +716% since its March 2026 IPO.
03International Markets
Desolate sentiment for China-linked exposure (CNI: −4.48% to −19.74% YTD) and profit-taking in Japan (IPJP: −4.54% to +52.36% YTD) weighed on the IPOX® International (IPXI: −3.28% to +5.93% YTD), while the IPOX® 100 Europe (IPOE: −1.25% to −1.53% YTD) fell less than the European market last week.
Big losses in Chinese battery maker CATL (3750 HK: −19.06%), after much worse-than-expected quarterly numbers, reinforced the negative momentum after midweek. Select health care stocks rose strongly after earnings, with the most upside recorded by French biotech Nanobiotix (NANO FP: +34.83%) and Belgium’s biopharma UCB (UCB BB: +33.28%).
In more biotech IPO news, we note last week’s big reversal in the much-touted research platform Iambic Therapeutics (IAM US: −40.11%). After gaining +49% in its first week, the stock now trades at an 11% discount to its October 15 IPO price.
04Performance Monitor
SELECT IPOX® STRATEGIES - PRICE RETURNSAs of October 23, 2026
SELECT IPOX® STRATEGIES - PRICE RETURNS As of October 23, 2026
| IPOX® Strategy | Week | YTD | 1Y |
|---|---|---|---|
| IPOX® Health Innovation | +2.40% | +4.74% | +9.73% |
| GINDEX® Growth Infusion U.S. | +1.29% | +16.03% | +16.67% |
| IPOX® Composite U.S. | +0.40% | +8.02% | +7.59% |
| IPOX® Global High Dividend 7% | +0.28% | +11.57% | +14.09% |
| IPOX® Alpha Plus Active | −0.15% | +15.14% | +7.32% |
| IPOX® 100 U.S.* † | −0.48% | +3.38% | +3.58% |
| IPOX® 100 Europe† | −1.25% | −1.53% | −1.55% |
| GINDEX® Growth Infusion International | −2.31% | +5.91% | +13.68% |
| IPOX® Global 50 Super Liquid | −3.20% | +15.17% | +14.68% |
| IPOX® International | −3.28% | +5.93% | +6.52% |
| IPOX® Greater China | −4.48% | −19.74% | −23.74% |
| IPOX® Japan | −4.54% | +52.36% | +71.25% |
Source: IPOX®
* Basis for CME-traded e-mini IPOX® 100 U.S. Futures (IPOZ6).
† Also available in UCITS format in Europe in EUR (EFPX IM), USD (IPXE LN), and GBP (FPX LN/FPXE LN).
05ECM Review
26 firms went public globally last week, raising a combined $3.24 billion. New listings gained an average of +26.72% from offer price to Friday’s close (median: +2.78%).
In the U.S., protein degradation therapeutics firm Lycia Therapeutics (LYCA US: +66.67%) raised $318 million. Other notable listings in accessible markets included Greek container shipping operator Capital Maritime Finance (CMFC GA: +0.40%, $336 million), South Korean AI cloud provider Elice (0158S0 KS: +4.09%, $145 million), Australian gold miner Wiluna Mining (WMC AU: −23.08%, $123 million) and New Zealand solar-energy-focused Lodestone Energy (LOD NZ: +2.22%, $57 million).
06Outlook
This week, at least six sizable IPOs are set to debut globally. Electronic components maker Precision Manufacturing (2384 HK, $1.36 billion) leads the calendar, followed by industrial robotics technology provider Microintelligence (3275 HK, $91 million).
Elsewhere, Taiwan-founded semiconductor materials firm Mi Material (MIM SP, $109 million), Japanese real estate firm Toggle (652A JP, $86 million), French sports nutrition and equipment retailer N4 Group (ALN4 FP, $56 million), precision engineering solutions provider TEK4 Group ($33 million) and South Korean industrial equipment maker TNE Korea (0053F0 KS, $28 million) are expected to list.
More spin-offs lined up
Spin-off activity also features prominently, with Madison Square Garden Sports planning to separate ice hockey franchise MSG Rangers (MSGR US, estimated valuation: $2.5 billion). The remaining firm is set to be renamed MSG Knicks (MSGK US), housing the basketball franchise at a valuation of about $7.5 billion.
Germany’s Thyssenkrupp industrial logistics unit Tk Accelis, valued at approximately $4 billion, is also lined up.
©2026 IPOX® Schuster LLC. IPOX® is an international trademark of IPOX® Schuster LLC. Index of Initial Public Offerings (IPOX®) and IPOX® Derivatives Patent No. US 7,698,197. Use of IPOX® and the IPOX® Indexes or any part thereof is subject to applicable license only. Nothing herein constitutes a recommendation or financial advice. This material is disseminated in the United States of America by IPOX® Schuster LLC. This material, or any portion thereof, may not be reprinted, sold, or redistributed without the written consent of IPOX® Schuster LLC.
For further information, please email info@ipox.com, call our team at 1-312-339-4114 or send mail to IPOX® Schuster LLC, 225 West Washington, Suite 1675, Chicago, IL 60606, U.S.A.

